Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Reneo Pharmaceuticals, Inc. (RPHM) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets June 30, 2023 December 31, 2022 Assets Current assets: Cash and cash equivalents $ 9,081 $ 19,927 Short-term investments 133,596 81,246 Prepaid expenses and other current assets 3,643 5,180 Total current assets 146,320 106,353 Property and equipment, net 554 453 Right-of-use assets 1,086 1,292 Other non-current assets 79 84 Total assets $ 148,039 $ 108,182 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,828 $ 1,893 Accrued expenses 11,592 4,827 Operating lease liabilities, current portion 318 404 Total current liabilities 13,738 7,124 Operating lease liabilities, less current portion 897 1,059 Performance award 876 29 Total liabilities 15,511 8,212 Commitments and contingencies Stockholders’ equity: Comm..."
05/11/2023 8-K Quarterly results
Docs: "Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results • Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023 • Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023 -- Reneo Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended March 31, 2023 and provided a business update. “In the first quarter we achieved a key milestone with the completion of enrollment of the pivotal STRIDE study. We have been encouraged by the patient interest in our mavodelpar program, which led to an ov..."
11/08/2022 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets September 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 62,132 $ 124,660 Short-term investments 53,948 23,010 Prepaid expenses and other current assets 4,918 6,064 Total current assets 120,998 153,734 Property and equipment, net 241 212 Right-of-use assets 1,186 — Other non-current assets 79 78 Total assets $ 122,504 $ 154,024 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 2,189 $ 2,022 Accrued expenses 6,851 4,180 Operating lease liabilities, current portion 410 — Total current liabilities 9,450 6,202 Operating lease liabilities, less current portion 943 — Other long-term liabilities — 167 Performance award 66 444 Total liabilities 10,459 6,813 Commitments and contingencie..."
08/09/2022 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. Consolidated Balance Sheets June 30, 2022 December 31, 2021 Assets Current assets: Cash and cash equivalents $ 118,264 $ 124,660 Short-term investments 8,588 23,010 Prepaid expenses and other current assets 5,159 6,064 Total current assets 132,011 153,734 Property and equipment, net 236 212 Right-of-use assets 1,283 — Other non-current assets 78 78 Total assets $ 133,608 $ 154,024 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,560 $ 2,022 Accrued expenses 6,367 4,180 Operating lease liabilities, current portion 408 — Total current liabilities 8,335 6,202 Operating lease liabilities, less current portion 1,061 — Other long-term liabilities — 167 Performance award 55 444 Total liabilities 9,451 6,813 Commitments and contingencies St..."
05/10/2022 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "RENEO PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS"
08/11/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy